Arizona State Retirement System lifted its holdings in shares of Global Blood Therapeutics, Inc. (NASDAQ:GBT – Get Rating) by 3.7% in the first quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 15,678 shares of the company’s stock after buying an additional 560 shares during the period. Arizona State Retirement System’s holdings in Global Blood Therapeutics were worth $543,000 as of its most recent filing with the SEC.
Other hedge funds and other institutional investors have also bought and sold shares of the company. Nisa Investment Advisors LLC grew its position in Global Blood Therapeutics by 75.6% during the 1st quarter. Nisa Investment Advisors LLC now owns 1,510 shares of the company’s stock worth $52,000 after acquiring an additional 650 shares during the last quarter. Advisor Group Holdings Inc. grew its position in Global Blood Therapeutics by 31.8% during the 4th quarter. Advisor Group Holdings Inc. now owns 1,865 shares of the company’s stock worth $55,000 after acquiring an additional 450 shares during the last quarter. Lazard Asset Management LLC grew its position in Global Blood Therapeutics by 31.4% during the 4th quarter. Lazard Asset Management LLC now owns 2,579 shares of the company’s stock worth $75,000 after acquiring an additional 617 shares during the last quarter. Victory Capital Management Inc. bought a new stake in Global Blood Therapeutics during the 4th quarter worth $225,000. Finally, Cambridge Investment Research Advisors Inc. bought a new stake in shares of Global Blood Therapeutics in the 4th quarter valued at about $243,000.
Wall Street Analyst Weigh In
A number of equities research analysts have commented on GBT shares. StockNews.com upgraded Global Blood Therapeutics from a “sell” rating to a “hold” rating in a research report on Thursday, May 5th. Oppenheimer reduced their price target on Global Blood Therapeutics from $86.00 to $71.00 in a research report on Thursday, May 5th. Wedbush set a $74.00 price target on Global Blood Therapeutics in a research report on Monday, June 20th. JPMorgan Chase & Co. reduced their price target on Global Blood Therapeutics from $39.00 to $36.00 and set a “neutral” rating on the stock in a research report on Tuesday, June 28th. Finally, Cantor Fitzgerald initiated coverage on Global Blood Therapeutics in a research report on Thursday, April 28th. They issued a “buy” rating and a $75.00 price target on the stock. Four research analysts have rated the stock with a hold rating and nine have issued a buy rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $58.67.
Insider Buying and Selling
Global Blood Therapeutics Stock Up 3.0 %
GBT stock opened at $33.93 on Thursday. The stock’s 50 day simple moving average is $30.02 and its 200 day simple moving average is $30.39. Global Blood Therapeutics, Inc. has a fifty-two week low of $21.65 and a fifty-two week high of $40.69. The company has a debt-to-equity ratio of 4.34, a quick ratio of 7.74 and a current ratio of 8.52. The company has a market cap of $2.21 billion, a P/E ratio of -6.97 and a beta of 0.83.
Global Blood Therapeutics (NASDAQ:GBT – Get Rating) last posted its quarterly earnings results on Wednesday, May 4th. The company reported ($1.26) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.29) by $0.03. Global Blood Therapeutics had a negative return on equity of 129.74% and a negative net margin of 146.82%. The business had revenue of $55.20 million for the quarter, compared to the consensus estimate of $56.13 million. During the same period in the prior year, the business earned ($1.21) EPS. The firm’s revenue for the quarter was up 41.5% on a year-over-year basis. On average, research analysts expect that Global Blood Therapeutics, Inc. will post -4.65 earnings per share for the current fiscal year.
Global Blood Therapeutics Profile
Global Blood Therapeutics, Inc, a biopharmaceutical company, engages in the discovery, development, and delivery of treatments for underserved patient communities with sickle cell disease (SCD). The company offers Oxbryta tablets, an oral, once-daily therapy for SCD. It also evaluates the safety and pharmacokinetics of single and multiple doses of Oxbryta in a Phase II a clinical trial of adolescent and pediatric patients with SCD.
- Get a free copy of the StockNews.com research report on Global Blood Therapeutics (GBT)
- There Are Different Types of Stock To Invest In
- Is it Time to Tap Molson Coors or Will Beer Sales Turn Flat?
- Is Starbucks Shooting For The Moon?
- PayPal Continues To Struggle As Competition Increases
- Two High-Yield Deep-Values You Shouldn’t Ignore
Want More Great Investing Ideas?
- Bear Market Game Plan!
- The 10 Best Stocks to Own in 2022
- 7 Stocks to Buy and Hold Forever
- 3 Stocks to DOUBLE This Year
Receive News & Ratings for Global Blood Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Global Blood Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.